Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 17

1474P - Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)

Date

10 Sep 2022

Session

Poster session 17

Topics

Tumour Site

Renal Cell Cancer

Presenters

Clara Iglesias Gómez

Citation

Annals of Oncology (2022) 33 (suppl_7): S660-S680. 10.1016/annonc/annonc1072

Authors

C. Iglesias Gómez1, V. Blanco Lorenzo2, R. Garcia Dominguez3, I. García Carbonero4, E. Feliciangeli5, S. Galvan Ruiz6, A. Gómez de Liaño7, B. Perez Valderrama8, A. Rodriguez Sanchez9, R. Sánchez-Escribano10, C. Suarez Rodriguez11, M. Lázaro Quintela12, E. Gallardo Diaz13, J. Guma I Padro14, J. Puente15, J.C. Villa Guzman16, J. García Sanchez17, M. Martinez Kareaga18, M.D.C. Beato Zambrano19, J. Molina-Cerrillo20

Author affiliations

  • 1 Medical Oncology Department, HUCA - Hospital Universitario Central de Asturias, 33011 - Oviedo/ES
  • 2 Pathology Department, HUCA - Hospital Universitario Central de Asturias, 33011 - Oviedo/ES
  • 3 Medical Oncology Department, University Hospital of Salamanca, 37007 - Salamanca/ES
  • 4 Medical Oncology Department, Hospital Virgen de la Salud, 49004 - Toledo/ES
  • 5 Dept. Oncology, Hospital Universitario Santa Lucia, 30202 - Cartagena/ES
  • 6 Medical Oncology Department, Hospital Universitario de Gran Canaria Doctor Negrin, 35010 - Las Palmas de Gran Canaria/ES
  • 7 Medical Oncology Department, Complejo Hospitalario Universitario Insular - Materno Infantil (CHUIMI), las Palmas de Gran Canaria/ES
  • 8 Dept. Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Seville/ES
  • 9 Medical Oncology Department, Complejo Asistencial Universitario de León - Hospital de León, 24071 - León/ES
  • 10 Medical Oncology Department, University Clinical Hospital of Valladolid, 47003 - Valladolid/ES
  • 11 Oncology Dept., Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 12 Dept. Oncology, Hospital Alvaro Cunqueiro, 36312 - Pontevedra/ES
  • 13 Oncology Department, Parc Tauli Hospital Universitari, 08208 - Sabadell/ES
  • 14 Oncology Department, Hospital Universitari Sant Joan de Reus, 43204 - Reus/ES
  • 15 Dept. Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 16 Medical Oncology Department, Hospital General Ciudad Real, 13005 - Ciudad Real/ES
  • 17 Medical Oncology Service, Hospital Arnau de Vilanova, 46015 - Valencia/ES
  • 18 Medical Oncology Department, Hospital Txagorritxu, 01009 - Vitoria/ES
  • 19 Medical Oncology Department, Hospital Universitario Virgen Macarena, 41009 - Seville/ES
  • 20 Medical Oncology Department, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1474P

Background

The current treatment landscape in mRCC is based on antiangiogenic and immune-based therapies demonstrating a significant improvement in survival. However, there is a paucity of well-validated prognostic and predictive biomarkers. The main objective was to evaluate the role of PD-L1 as an independent prognostic factor in a cohort of mRCC patients treated only with antiangiogenic agents.

Methods

Retrospective, multicentre (25 centres) study on patients (pts) that had received antiangiogenic drugs, but no immune based therapies, during treatment sequence. Demographic and tumor-related data were obtained from medical records. PD-L1 expression (22C3 pharmDx) from primary tumor tissues were centrally obtained. Univariable and multivariable log-rank test and Cox regressive models were used.

Results

242 out of 340 pts (71.2%) were assessable, mean age was 64.0 (SD 11.5) years and 185 (76.4%) were men. According to the IMDC score; 13 pts (7.8%) had favourable, 92 (55.4%) intermediate and 61 (36.7%) poor prognosis. 113 pts (46.7%) received a single line of antiangiogenics. Sunitinib was chosen as first line in 70.7% and pazopanib in 26%. PD-L1 tumor expression was <1% in 205 (84.7%) and >1% in 37 (15.3%) of the samples. Overall survival (OS) showed statistically differences according to PD-L1 expression (median of 14.5 months (m) for PD-L1 <1% vs 9.7m for PD-L1 ≥1%) (p=0.0023). OS based on the IMDC score was [median (m;95%CI)]: for the favourable [37.8m;3.7-49.1)], intermediate [15.1m (12.3-20.8)] and poor 4.2m (2.1-7.3) prognosis groups (p<0.05). The multivariable analysis identified the worst survival for PD-L1 expression ≥1 % (HR 0.62 (0.41-0.93), p=0.0216), poor IMDC prognosis criteria (HR 0.40 (0.28-0.57), p<0.05) and more than one metastatic location (HR 0.66 (0.48-0.91), p=0.0106).

Conclusions

To our knowledge, this is the first study analyzing the value of PD-L1 expression in a population of mRCC pts who had died and treated exclusively with antiangiogenics. The results of our analyses show that PD-L1 expression has a prognostic role in mRCC pts, suggesting its value as an indication of using check-point inhibitors from the first line and not only antiangiogenic drugs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

SOGUG.

Funding

Pfizer S.L.U.

Disclosure

E. Feliciangeli: Financial Interests, Personal, Invited Speaker: GP Pharma, Servier, Astellas. S. Galvan Ruiz: Financial Interests, Personal, Invited Speaker: Astellas, Ipsen, Ipsen, Pfizer, Servier, Merck, Roche; Financial Interests, Personal, Advisory Board: Ipsen, BMS, BMS, Lilly, Ipsen. A. Gómez de Liaño: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Ipsen, Janssen, MSD, Pfizer; Financial Interests, Personal, Advisory Board: Astellas, BMS, Ipsen, Merck, Janssen, Pfizer, Roche; Financial Interests, Personal, Training: MSD; Financial Interests, Personal, Expert Testimony: Roche; Financial Interests, Institutional, Principal Investigator: AstraZeneca, MedSIR. B. Perez Valderrama: Financial Interests, Personal, Advisory Board: Pfizer, Astellas Pharma, Bristol Myers Squibb, Ipsen, EUSA Pharma, Sanofi-Aventis, Merck, MSD, AstraZeneca; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Roche, Bayer, EUSA Pharma, MSD, Merck, Pfizer, Janssen, Astellas Pharma. A. Rodriguez Sanchez: Financial Interests, Personal, Advisory Board: Roche, Janssen, Sanofi, Merck, Ipsen, Eisai, Bristol. C. Suarez Rodriguez: Financial Interests, Personal, Advisory Board: Astellas Pharma, Bayer, Bristol Myers Squibb (Inst), Ipsen, Pfizer S.L.U, Sanofi- Aventis, Hoffmann-La Roche Ltd., Merck Sharp and Dohme; Financial Interests, Personal, Invited Speaker: Astellas Pharma, Bristol Myers Sqquib (Inst), Ipsen, Pfizer S.L.U, Hoffmann-La Roche Ltd.; Financial Interests, Institutional, Funding: Ipsen. M. Lázaro Quintela: Financial Interests, Personal, Other: Pfizer, Lilly, MSD, BMS, Astellas, Janssen, Ipsen, Bayer, Roche, AstraZeneca, Boheringer, Takeda; Financial Interests, Personal and Institutional, Principal Investigator: Mirati, Roche, AstraZeneca, Janssen. E. Gallardo Diaz: Financial Interests, Personal, Advisory Board: Sanofi, Janssen, Astellas, Pfizer, Bayer, Roche, Ipsen, Eisai, EUSA Pharma, BMS, AstraZeneca, Merck, Daiichi Sankyo, Techdow, Lilly; Financial Interests, Personal, Invited Speaker: Sanofi, Janssen, Astellas, Pfizer, Bayer, Roche, Ipsen, Eisai, EUSA Pharma, BMS, Merck, Daiichi Sankyo, MSD, Menarini, Rovi, Leo Pharma, Boehringer Ingelheim; Financial Interests, Personal, Expert Testimony: Merck, Novartis, Pfizer; Financial Interests, Institutional, Invited Speaker: Astellas, Medivation, Ipsen, Janssen, Pfizer, Lilly, Pfizer-Merck, MSD, BMS, Bayer, Daiichi Sankyo, Roche, AstraZeneca, Novartis, Seattle Genetics, Incyte, Aveo, Exelixis, Immunicum, Mediolanum, Clovis, QED Therapeutics; Non-Financial Interests, Leadership Role, Member of the Board: SOGUG; Non-Financial Interests, Leadership Role, Member of the Board of Thrombosis and Cancer Section: SEOM. J. Guma I Padro: Financial Interests, Personal, Advisory Board: Sanofi/aventis, Kite/Gilead; Financial Interests, Personal, Other: Sanofi/aventis. J. Puente: Financial Interests, Personal, Invited Speaker: Astellas, Janssen, Bayer, AstraZeneca, Ipsen, Roche, BMS, Merck, Pfizer; Financial Interests, Personal, Advisory Board: Eisai. M. Martinez Kareaga: Other, Personal, Invited Speaker: Roche, Bristol Myers Squibb; Other, Personal, Advisory Board: Merck. M.D.C. Beato Zambrano: Financial Interests, Personal, Other: Roche, Pfizer, BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.